Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy
Condition(s):Relapsed/Refractory Large B Cell LymphomaLast Updated:December 14, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Relapsed/Refractory Large B Cell LymphomaLast Updated:December 14, 2023Recruiting
Condition(s):Lymphoma, Large B-Cell, DiffuseLast Updated:March 12, 2024Not yet recruiting
Condition(s):Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Unresectable MelanomaLast Updated:February 28, 2024Recruiting
Condition(s):Metastatic MelanomaLast Updated:January 9, 2024Active, not recruiting
Condition(s):Metastatic MelanomaLast Updated:February 14, 2024Active, not recruiting
Condition(s):Metastatic MelanomaLast Updated:January 8, 2024Active, not recruiting
Condition(s):Acute Myeloid LeukemiaLast Updated:September 28, 2023Completed
Condition(s):Leukemia, B-CellLast Updated:February 2, 2024Recruiting
Condition(s):B Cell LymphomaLast Updated:May 26, 2022Recruiting
Condition(s):DLBCL – Diffuse Large B Cell LymphomaLast Updated:December 12, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.